Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Viatris (GB:0A5V)
LSE:0A5V
Holding GB:0A5V?
Track your performance easily
0A5V Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$8.77 - $13.61
Previous Close$12.05
Volume2.72K
Average Volume (3M)9.64K
Market Cap
$14.20B
Enterprise Value$30.38B
Total Cash (Recent Filing)$917.20M
Total Debt (Recent Filing)$17.10B
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Nov 07, 2024EPS Estimate
$0.69Last Dividend Ex-Date
Aug 23, 2024Dividend Yield4.03%
Share Statistics
EPS (TTM)-0.54
Shares Outstanding1,193,520,463
10 Day Avg. Volume3,232
30 Day Avg. Volume9,644
Standard Deviation0.09
R-Squared0.16
Alpha-0.00206
Financial Highlights & Ratios
Price to Book (P/B)0.68
Price to Sales (P/S)0.93
Price to Cash Flow (P/CF)9.40
P/FCF Ratio7.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.99
Enterprise Value/Gross Profit4.72
Enterprise Value/Ebitda19.30
Forecast
1Y Price Target
$12.75Price Target Upside5.82% Upside
Rating ConsensusHold
Number of Analyst Covering4
Viatris News
PremiumCompany Announcements
Viatris Initiates Cash Tender Offers for Senior Notes
Bulls Say, Bears Say
Bulls Say
Financial PerformanceStrong pipeline and increased R&D focus position the company well to deliver strong performance in the long term.
Operational GrowthThe company has returned to positive operational growth, has a strong pipeline of complex products, a healthy balance sheet, and strong free cash flow.
Revenue OutlookImproving China revenue outlook positions the company for better performance.
Bears Say
EarningsModest 2Q beats don’t materially alter growth outlook.
Growth ChallengesGiven legacy growth challenges, the Viatris’ growth story is viewed as show-me.
Growth TrajectoryRevenue and EBITDA for 2024 are expected to be lower due to the impact of the OTC sale.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.90% Insiders
23.69% Mutual Funds
51.00% Other Institutional Investors
24.41% Public Companies and
Individual Investors
0A5V FAQ
What was Viatris’s price range in the past 12 months?
Viatris lowest share price was $8.77 and its highest was $13.61 in the past 12 months.
What is Viatris’s market cap?
Currently, no data Available
When is Viatris’s upcoming earnings report date?
Viatris’s upcoming earnings report date is Nov 07, 2024 which is in 48 days.
How were Viatris’s earnings last quarter?
Viatris released its earnings results on Aug 08, 2024. The company reported $0.69 earnings per share for the quarter, beating the consensus estimate of $0.678 by $0.012.
Is Viatris overvalued?
According to Wall Street analysts Viatris’s price is currently Undervalued.
Does Viatris pay dividends?
Viatris pays a Quarterly dividend of $0.12 which represents an annual dividend yield of 4.03%. See more information on Viatris dividends here
What is Viatris’s EPS estimate?
Viatris’s EPS estimate is $0.69.
How many shares outstanding does Viatris have?
Viatris has 1,193,520,500 shares outstanding.
What happened to Viatris’s price movement after its last earnings report?
Viatris reported an EPS of $0.69 in its last earnings report, beating expectations of $0.678. Following the earnings report the stock price went up 5.041%.
Which hedge fund is a major shareholder of Viatris?
Among the largest hedge funds holding Viatris’s share is Davis Selected Advisers. It holds Viatris’s shares valued at 612M.
---
Viatris Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$12.75 (5.82% Upside)
$12.75 (5.82% Upside)
Blogger Sentiment
Bullish
GB:0A5V Sentiment 92%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $7.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
25.75%
12-Months-Change
Fundamentals
Return on Equity
-3.20%
Trailing 12-Months
Asset Growth
-6.91%
Trailing 12-Months
Company Description
Viatris
Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.
---
0A5V Company Deck
---
0A5V Earnings Call
Q2 2024
0:00 / 0:00
---
0A5V Net sales Breakdown
63.69% Brands
36.31% Generics
---
0A5V Stock 12 Month Forecast
Average Price Target
$12.75
▲(5.82% Upside)
Technical Analysis
Viatris
―
Merck & Company
―
Bristol-Myers Squibb
―
Johnson & Johnson
―
Perrigo Company
―
Best Analysts Covering 0A5V
1 Year
1 Year Success Rate
6/23 ratings generated profit
1 Year Average Return
-9.67%
reiterated a sell rating last month
Copying Jason Gerberry's trades and holding each position for 1 Year would result in 26.09% of your transactions generating a profit, with an average return of -9.67% per trade.
---